ÃÑ 76ÆäÀÌÁö

73ÆäÀÌÁö º»¹®½ÃÀÛ

¢Â Âü°í¹®Çå ¢Â
¡¤ÀǾàÇ°Á¦Á¶¹×Ç°Áú°ü¸®¿¡°üÇѱÔÁ¤,½ÄÇ°ÀǾàÇ°¾ÈÀüó°í½ÃÁ¦2020-105È£,(2020.10.28.)
¡¤¿ÏÁ¦ÀǾàÇ°Á¦Á¶¹×Ç°Áú°ü¸®±âÁØ°¡ÀÌ´ø½º(¹Î¿øÀξȳ»¼­),½ÄÇ°ÀǾàÇ°¾ÈÀüó(2021.6.9.)
¡¤¼¼Ã´¹ë¸®µ¥À̼ÇÇÁ·ÎÅäÄÝ(¹Î¿øÀξȳ»¼­),½ÄÇ°ÀǾàÇ°¾ÈÀüó(2009)
¡¤Goodmanufacturingpracticesforpharmaceuticalproducts:mainprinciples,WHO,2014(WHO
TechnicalReportSeries986)
¡¤Good manufacturing practices: guidelines on validation, WHO, 2021. (WHO Technical Report
Series1019)
¡¤Draft working document for comments: Points to consider when including HBELs in cleaning
validation,WHO,WorkingdocumentQAS/20.849/Rev.1,August2020
¡¤GuidetoGoodManufacturingPracticeforMedicinalProductsPart1,PIC/S,2021
¡¤Cross-ContaminationinSharedFacilities,PIC/S,2018
¡¤ValidationofCleaningProcesses(7/93),USFDA
¡¤Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Guide for
Industry,USFDA,2016
¡¤EU Guidelines for Good Manufacturing Practice for medicinal Products for Human and
VeterinaryUSE.Part1,Chapter5:Production,EuropeanCommision,August,2014
¡¤EU Guidelines for Good Manufacturing Practice for medicinal Products for Human and
VeterinaryUSE.Annex15:QualificationandValidation,EuropeanCommision,March,2015
¡¤Cleaningvalidationguide(GUI-0028),Canada,June2021
¡¤Guidance on Aspects of Cleaning Validation in Active Pharmaceutical Ingredient Plants, APIC,
September201
73

73ÆäÀÌÁö º»¹®³¡



ÇöÀç Æ÷Ä¿½ºÀÇ ¾Æ·¡³»¿ëµéÀº µ¿ÀÏÇÑ ÄÁÅÙÃ÷¸¦ °¡Áö°í ÆäÀÌÁö³Ñ±è È¿°ú¹× ½Ã°¢Àû È¿°ú¸¦ Á¦°øÇÏ´Â ÆäÀÌÁöÀ̹ǷΠ½ºÅ©¸°¸®´õ »ç¿ëÀÚ´Â ¿©±â±îÁö¸¸ ³¶µ¶ÇϽðí À§ÀÇ ÆäÀÌÁöÀ̵¿ ¸µÅ©¸¦ »ç¿ëÇÏ¿© ´ÙÀ½ÆäÀÌÁö·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
»ó´Ü¸Þ´º ¹Ù·Î°¡±â ´ÜÃàÅ°¾È³» : ÀÌÀüÆäÀÌÁö´Â ÁÂÃø¹æÇâÅ°, ´ÙÀ½ÆäÀÌÁö´Â ¿ìÃø¹æÇâÅ°, ùÆäÀÌÁö´Â »ó´Ü¹æÇâÅ°, ¸¶Áö¸·ÆäÀÌÁö´Â ÇϴܹæÇâÅ°, ÁÂÃøÈ®´ëÃà¼Ò´Â insertÅ°, ¿ìÃøÈ®´ëÃà¼Ò´Â deleteÅ°